[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"distal-pancreatectomy-dp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:distal-pancreatectomy-dp":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,59],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100588255","laparoscopic-versus-robot-assisted-left-sided-pancreatectomy-for-benign-and-pre-malignant-lesions-diploma-3-100588255",false,"NCT06939023","Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3)","Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3): an International Multicenter Patient-blinded Randomized Controlled Trial","DIPLOMA-3","Inclusion Criteria:\n\n* Age at least 18 years;\n* Indication for elective left-sided pancreatectomy, either spleen-preserving or non-preserving (because of proven or suspected left-sided benign or premalignant disease);\n* Both robot-assisted and laparoscopic left-sided pancreatectomy are technically feasible for resection, according to the local treatment team;\n* Fit to undergo left-sided pancreatectomy according to the surgeon and anaesthesiologist;\n* Written informed consent\n\nExclusion Criteria:\n\n* Suspected pancreatic ductal adenocarcinoma;\n* Tumor or cyst larger than 8 cm;\n* Required resection or ablation of organs other than pancreas and spleen;\n* Tumor involvement or abutment of major vessels (celiac trunk, mesenteric artery or vena cava);\n* Pregnancy;\n* Body mass index \\>40 kg\u002Fm2;\n* Participation in another study with interference of study outcomes","ALL","18 Years",{"count":20,"type":21},256,"ESTIMATED","INTERVENTIONAL",[24],"NA","The DIPLOMA-3 trial is an international, multicenter, patient-blinded randomized controlled trial comparing laparoscopic and robot-assisted left-sided pancreatectomy. Patients with an indication for elective left-sided pancreatecomy for benign or premalignant lesions in the body or tail of the pancreas and considered eligible will be randomized between laparoscopic and robot-assisted resection.",[27,28,29,30,31,32,33,34,35,36],"Pancreatectomy","Distal Pancreatectomy (DP)","Pancreatic Neoplasms","Pancreatic Adenoma","Pancreatic Cyst","Pancreatic Cystadenoma","Surgery","Minimally Invasive Surgical Technique","Minimally Invasive Distal Pancreatectomy","Minimally Invasive Surgery",[38,39,40,41,42,43,44,45],"pancreas surgery","left-sided pancreatectomy","distal pancreatectomy","minimally invasive surgery","robot-assisted pancreatectomy","left pancreatectomy","robotic pancreatectomy","laparoscopic pancreatectomy","RECRUITING","2025-08-28",{"date":49,"type":50},"2025-09-04","ACTUAL",{"date":52,"type":50},"2025-06-01",{"date":54,"type":21},"2028-06-01",{"name":56,"class":57},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":69,"conditions":70,"keywords":71,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100600294","feasibility-and-effectiveness-of-three-day-discharge-after-distal-pancreatectomy-100600294","NCT07095621","Feasibility and Effectiveness of Three-day Discharge After Distal Pancreatectomy","3DD","Inclusion Criteria:\n\n* adult (age\\>= 18 years) patients undergoing elective minimally invasive distal pancreatectomy\n* patients residing or with a temporary accommodation within 50 km or a 30-minute drive from the hospital;\n* patients with an adequate support system at home (defined as 24-hour support for at least the first POD7);\n* no contraindications to intrathecal or opioid-sparing analgesia;\n* patient who have signed the inform consent for participation in the trail;\n* No preoperative medical issue requiring inhospital observation longer than three days\n\nExclusion Criteria:\n\n* Patients undergoing multi-visceral resection;\n* undergoing an open procedure;\n* requiring vascular resection;\n* having a history of chronic opioid use;\n* having significant comorbidities or an American Society of Anesthesiologists (ASA) score \\> 3;\n* patients unabled to speak Italian;\n* having a cognitive impairment;\n* develoing intraoperative complications;\n* difficulty to be reached after discharge (e.g., limited access to a telephone).",{"count":67,"type":21},35,"OBSERVATIONAL","Background: Enhanced recovery after surgery (ERAS) programs and the minimally invasive approach have significantly improved recovery outcomes following distal pancreatectomy (DP). Nevertheless, most patients stay in the hospital a median of 7 postoperative days after laparoscopic DP, despite achieving functional recovery 3-4 days earlier. Early discharge protocols have proven to be safe and feasible If selected patients.\n\nResearch objectives: This study aims to evaluate the feasibility and effectiveness of a three-day discharge (3DD) protocol for patients undergoing minimally invasive DP.\n\nStudy design: This is an observational, prospective cohort study that will be conducted at San Raffaele Hospital (Milan, Italy) Primary Objective: To investigate the feasibility of a 3-day discharge protocol following a minimally invasive distal pancreatectomy, with post-discharge phone follow-up conducted by a nurse navigator.\n\nSecondary Objective: To investigate the effectiveness of a 3-day discharge protocol following a minimally invasive distal pancreatectomy, evaluate the rate of 30-day emergency departement visits, hospital readmission and patient satisfaction Population: All adult patients undergoing elective minimally invasive distal pancreatectomy who meet the following inclusion criteria will be included in this study\n\n* adult (age\\>= 18 years) patients undergoing elective minimally invasive distal pancreatectomy\n* patients residing or with a temporary accommodation within 50 km or a 30-minute drive from the hospital;\n* patients with an adequate support system at home (defined as 24-hour support for at least the first POD7);\n* no contraindications to intrathecal or opioid-sparing analgesia;\n* patient who have signed the inform consent for participation in the trail;\n* No preoperative medical issue requiring inhospital observation longer than three days Patients scheduled for elective minimally invasive DP, eligible for the study and willing to participate will be asked to sign the consent form in person during the preoperative counseling session.\n\nParticipants will receive comprehensive preoperative education and will be enrolled in an ERAS protocol that includes urinary catheter removal, initiation of a solid food diet, cessation of intravenous infusions, and oral pain management starting on postoperative day (POD 1). Following discharge on POD3, patients will receive a daily telephonic follow-up by a nurse navigator for the first 7 days after surgery (POD 7).\n\nPreoperatively: patients will complete in person during the counseling visit Patient-Reported Outcomes Measurement Information System (PROMIS)-29 questionnaire and patient-activation measure (PAM) - 13 questionnaires.\n\nAt discharge: patients will complete in person in the department PROMIS-29 questionnaire.\n\nAt 30 days after surgery, patients satisfaction will be assessed Duration of subject participation: 6 months Duration of total study period: 18 months",[29,28],[72,73],"pancreatic disease","early discharge","NOT_YET_RECRUITING","2025-08-03",{"date":77,"type":50},"2025-08-07",{"date":79,"type":21},"2025-09-13",{"date":81,"type":21},"2026-12-31",{"name":83,"class":57},"IRCCS San Raffaele"]